DataLend: Securities Lending Revenue Down 16% Year-Over-Year to $2.53 Billion in Q2 2024
Global revenue declines year-over-year due to lagging equities performance in the U.S. and EMEA NEW YORK, July 2, 2024 /PRNewswire/ -- The global securities finance industry generated $2.53 billion i
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Bilibili Inc. (NASDAQ:BILI) shares rose 23.32% following last week's release of 'San Guo: Mou Ding Tian Xia.'
ImmunityBio Shares Are Trading Higher on Continued Strength After the Company on Thursday Announced Insurance Coverage of ANKTIVA Across Multiple States With First Commercial Doses Administered.
ImmunityBio Shares Are Trading Higher on Continued Strength After the Company on Thursday Announced Insurance Coverage of ANKTIVA Across Multiple States With First Commercial Doses Administered.
Sector Update: Health Care Stocks Mixed Thursday Afternoon
Health care stocks were mixed Thursday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) rose 0.9%. In
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results.Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, be
Why ImmunityBio Stock Is Trading Higher Thursday
ImmunityBio, Inc. (NASDAQ:IBRX) shares are moving higher Thursday after the company announced insurance coverage of ANKTIVA across multiple states.The Details: ANKTIVA is a immunotherapy used to treat
ImmunityBio Spikes After Commercial Update on Lead Drug Anktiva
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday.Shares of KB Home (NYSE:KBH) rose during Thursday's session as the company posted better-than-expected earnings a
Express News | ImmunityBio Shares Are Trading Higher After the Company Announced Insurance Coverage of ANKTIVA Across Multiple States With First Commercial Doses Administered
ImmunityBio's Bladder Cancer Treatment Anktiva Launches in US
ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US
Express News | Immunitybio Announces Insurance Coverage of Anktiva® Across Multiple States With First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) Largest Shareholder Sees Value of Holdings Go Down 4.5% After Recent Drop
Key Insights ImmunityBio's significant insider ownership suggests inherent interests in company's expansion The top 2 shareholders own 62% of the company Institutional ownership in ImmunityBio is
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Express News | Immunitybio Announces 2024 Annual Meeting of Stockholders With Company Update
ImmunityBio, LadRx End Licensing Deal for Cancer Drug
Express News | Ladrx and Immunitybio Mutually Agree to Terminate Aldoxorubicin License
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
How Is The Market Feeling About ImmunityBio?
ImmunityBio's (NYSE:IBRX) short percent of float has fallen 8.79% since its last report. The company recently reported that it has 55.14 million shares sold short, which is 35.26% of all regular share
ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
ImmunityBio | 10-Q: Quarterly report